| Literature DB >> 34319149 |
Paraskevi C Fragkou1, Dimitra Dimopoulou2, George Latsios3, Panagiotis Koudounis4, Andreas Synetos3, Anastasia Dimopoulou5, Konstantinos Tsioufis3, Vassiliki Papaevangelou2, Sotirios Tsiodras1.
Abstract
Cardiopulmonary resuscitation (CPR) is an emergency lifesaving endeavor, performed in either the hospital or outpatient settings, that significantly improves outcomes and survival rates when performed in a timely fashion. As with any other medical procedure, CPR can bear potential risks not only for the patient but also for the rescuer. Among those risks, transmission of an infectious agent has been one of the most compelling triggers of reluctance to perform CPR among providers. The concern for transmission of an infection from the resuscitated subject may impede prompt initiation and implementation of CPR, compromising survival rates and neurological outcomes of the patients. Infections during CPR can be potentially acquired through airborne, droplet, contact, or hematogenous transmission. However, only a few cases of infection transmission have been actually reported globally. In this review, we present the available epidemiological findings on transmission of different pathogens during CPR and data on reluctance of health care workers to perform CPR. We also outline the levels of personal protective equipment and other protective measures according to potential infectious hazards that providers are potentially exposed to during CPR and summarize current guidelines on protection of CPR providers from international societies and stakeholders.Entities:
Keywords: COVID-19; SARS-CoV-2; airborne; blood-borne; cardiopulmonary; infection; resuscitation; transmission
Mesh:
Year: 2021 PMID: 34319149 PMCID: PMC8404692 DOI: 10.1128/CMR.00018-21
Source DB: PubMed Journal: Clin Microbiol Rev ISSN: 0893-8512 Impact factor: 26.132
Pathogens categorized by mode of transmission and examples of procedures undertaken during CPR that can be transmitted
| Mode of transmission | Pathogens | Examples of condition(s) leading to transmission during CPR |
|---|---|---|
| Direct transmission | ||
| Contact with blood (blood-borne) | HIV*, HBV*, HCV*, Ebola | Needlestick injury during cannulation and blood sampling |
| Contact with body fluids | Ebola, CCHF virus, | Contact with pleural fluid during insertion of ICD, contact with saliva during mouth-to-mouth ventilation, contact with feces |
| Contact with skin | VZV, HSV, HPV*, | Chest compressions without gloves, mouth-to-mouth ventilation |
| Contact with contaminated surfaces | Influenza, | Unprotected handling of equipment |
| Droplet transmission (>5-μm droplet diam) | SARS-CoV-2, MERS-CoV, influenza, CMV | Intubation, suctioning of secretion, administration of nebulized drugs |
| Indirect transmission | ||
| Airborne transmission | Measles, VZV, | Unprotected |
*, requires skin breach. Abbreviations: CCHF virus, Crimean-Congo hemorrhagic fever virus; CMV, cytomegalovirus; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSV, herpes simplex virus; ICD, intercostal chest drain; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VZV, varicella-zoster virus.
Selection of pathogens that can be possibly transmitted during CPR
| Pathogen | High-risk exposure | PEP | Preventative measures for HCWs |
|---|---|---|---|
| Viruses | |||
| Crimean-Congo hemorrhagic fever virus | Unprotected contact with infectious fomites, blood and body fluids including parenteral exposures to infectious blood or body fluids | Ribavirin (uncertain evidence for its efficacy) | PPE, hand hygiene, proper cleaning and disposal of medical equipment |
| Cytomegalovirus | Droplets, aerosol or direct contact, contact with contaminated surfaces or body fluids | NA | Hand hygiene, avoid oral contact, sharing objects that have contact with saliva, particularly when you are pregnant or immunocompromised |
| Ebola virus | Direct contact with infected blood or body fluids | Isolation | PPE, hand hygiene, proper cleaning and disposal of medical equipment, rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) (approved by the FDA for adults at potential risk of exposure to Ebola – including HCWs) |
| Hepatitis B virus | Percutaneous, mucosal, or nonintact skin exposure to infectious blood or body fluids | HBIG alone or in combination with HepB vaccination within 24 h | HepB vaccination, HBIG adjunct to HepB vaccination |
| Hepatitis C virus | Parenteral exposures to infectious blood or body fluids that contain blood | Baseline and follow-up testing, immunoglobulin not effective, no data for use on antivirals | Personal protective equipment |
| Herpes simplex virus 1 | Oral-to-oral contact, oral-to-genital contact | Acyclovir soon after mouth-to-mouth ventilation | Avoid oral contact, sharing objects that have contact with saliva |
| Human immunodeficiency virus | Needlestick injury involving infected blood, fluid splashes to mucus membranes extremely rare | Tenofovir, emtricitabine, and raltegravir within 72 h | Standard precautions (gloves, googles, hand hygiene, safety devices to prevent needlestick) |
| Influenza virus (seasonal, avian) | Direct contact with infectious droplets (and during aerosol producing procedures) | Oseltamivir, inhaled zanamivir (zanamivir is not recommended for people with underlying respiratory disease) | Hand hygiene, PPE, airborne isolation precautions |
| Measles | Direct contact with infectious droplets or by airborne spread | MMR vaccine within 72 h or immunoglobulin within 6 days of exposure | MMR vaccine, airborne isolation precautions |
| MERS-CoV | Through respiratory secretions/airborne spread | NA | Hand hygiene, PPE, airborne isolation precautions |
| SARS-CoV-2 | Exposure of eyes, nose, or mouth to material potentially containing SARS-CoV-2, particularly if present in a room for an aerosol-generating procedure (prolonged [>15-min] close contact, or independently of time if aerosol-generating procedure) | NA | Hand hygiene, PPE, airborne isolation precautions |
| Varicella-zoster virus | Droplets, aerosol, or direct contact | Varicella vaccine within 5 days from exposure; pregnant women, neonates, or immunocompromised persons: varicella-zoster immune globulin | Varicella vaccine |
| Bacteria | |||
|
| Airborne transmission from patients with TB disease of the lungs or throat | If tuberculin skin test is ≥5 mm or the interferon assay is positive, isoniazid plus vitamin B6 for 9 mo | Isoniazid, rifapentine, rifampin (various combinations and duration), BGC vaccination |
|
| Close contact with respiratory and throat secretions | Ciprofloxacin or azithromycin or ceftriaxone or rifampin as early as possible | Meningococcal vaccine |
| Fecal-oral route | NA | Hand hygiene | |
| | Fecal-oral transmission (foodborne and waterborne infection) | Isolation | Hand hygiene |
| Syphilis | Sexually transmitted (genital-fecal-oral), mother to infant, blood transfusion, direct contact with syphilis ulcer | Single dose of benzathine penicillin G (2.4 million units) | Contact of patient with gloves |
The most important pathogens potentially transmitted during CPR, definition of high-risk exposure, and recommended postexposure prophylaxis (PEP) for each pathogen are included. Abbreviations: CMV, cytomegalovirus; HBIG, hepatitis B immune globulin; HCWs, health care workers; HepB, hepatitis B vaccination; MERS-CoV, Middle East respiratory syndrome coronavirus; MMR, measles, mumps, rubella; NA, not applicable; PEP, postexposure prophylaxis; PPE, personal protective equipment; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Willingness of HCWs to perform CPR and mouth-to-mouth resuscitation
| Reference | Yr/country | No. of participants | Willingness of HCWs to perform CPR and mouth-to-mouth resuscitation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Strangers | Children | Trauma | HIV or high-risk persons for HIV | Elderly | Infection | With barrier device | |||
| Hew et al. ( | 1997/USA | 104 HCWs (74% EMTs, 26% paramedics) | EMTs, 43%; paramedics, 0% | EMTs, 77%; paramedics, 63% | EMTs, 25%; paramedics, 0% | Homosexuals: EMTS, 33%; paramedics, 0% | EMTs, 40%; paramedics: 4% | (–) | 98% |
| Horowitz et al. ( | 1997/USA | 379 HCWs (20% physicians, 63% nurses, 17% paramedics) | 35% | 57% | (–) | HIV-negative adults, 62–65%; HIV-negative children, 75% | (–) | (–) | (–) |
| Melanson et al. ( | 2000/USA | 342 HCWs (92% paramedics, 8% nurses) | ≤5% | 52% | (–) | 0% | (–) | (–) | HIV, 47%; other, >60% |
| Locke et al. ( | 1995/USA | 975 participants (20% HCWs, 80% lay persons) | MTM, 15%; compression-only, 68% | (–) | (–) | (–) | (–) | (–) | (–) |
| Boucek et al. ( | 2009/USA | 560 HCWs (26% physicians, 29% nurses, 13% EMTs and paramedics, 13% medical students, 6% nursing students, 13% other HCWs) | 38% | Own child, 96%; neighbor’s child, 78.5% | (–) | HIV, 16%; drug overdose, 6% | 46% | Ebola, 0.1%; TB, 6%; herpes, 4%; rabies, 6%; URI, 7%; antibiotic-resistant pneumonia, 19% | (–) |
| Ornato et al. ( | 1990/USA | 1,794 BLS instructors (87% HCWs [8% physicians, 50% nurses, 9% allied HCWs, 20% EMTs and paramedics]) | Male, 18–29%; female, 54% | 97% | (–) | HIV, 40%; drug overdose, 10%; hemophiliac, 35% | (–) | (–) | (–) |
| Brenner et al. ( | 1993/USA | 585 HCWs (74% physicians, 26% nurses) | Physicians, 57%; nurses, 20% | Physicians, 84%; nurses, 78% | Physicians, 55%; nurses, 38% | Homosexuals: physicians, 17%; nurses, 9% | Physicians, 57%; nurses, 35% | (–) | (–) |
| Brenner et al. ( | 1994/USA | 74 HCWs (100% physicians) | 45% | (–) | 26% | Homosexuals, 7% | 39% | (–) | (–) |
| Brenner et al. ( | 1996/USA | 140 HCWs (100% physicians) | Inpatient, 43–45%; outpatient, 50–54% | Outpatient, 86–99% | Inpatient, 12–16%; outpatient, 33–36% | HIV: inpatient, 7–14%; outpatient, 21–34% | Inpatient, 29–39%; outpatient, 26–64% | (–) | (–) |
High-risk persons for HIV: homosexual, drug overdose, and hemophiliac. Abbreviations: HCWs, health care workers; CPR, cardiopulmonary resuscitation; BLS, basic life support; MTM, mouth-to-mouth resuscitation; EMTs, emergency medical technicians; URI, upper respiratory infection; HIV, human immunodeficiency virus. (–), no data.
FIG 1Levels of personal protective equipment (PPE).
FIG 2Suggested algorithm for cardiopulmonary resuscitation (CPR) and personal protective equipment (PPE) in patients with airborne or droplet transmitted infection.
FIG 3Suggested algorithm for cardiopulmonary resuscitation (CPR) and personal protective equipment (PPE) in patients with bloodborne infection or infection transmitted through contact with skin or other body fluids.